

DSEX WENT DOWN BY 42.4 POINTS

Market closed negative today with decrease in turnover.


Broad index DSEX went down by 42.4 points.

No sector closed positive today. Paper & Printing, Jute and Ceramics are the top three sectors that closed negative today.


Turnover decreased by 11.2% to BDT 6,547mn (USD 53mn).

Pharma sector dominated the turnover chart covering 14.8% of the total turnover.


Intraday Performance of DSEX




Sector Return



Sector P/E



52 Week Daily Turnover & DSEX



Index

Particulars	Value	Δ Points	Daily Δ %	Dec'24 Value	YTD Δ %
DSEX	5,449.93	(42.4)	-0.77%	5,216.44	4.48%
DS30	2,107.14	(20.0)	-0.94%	1,939.73	8.63%
DSES	1,178.20	(13.1)	-1.10%	1,168.90	0.80%
S&P 500	6,395.78	(15.5)	-0.24%	5,881.63	8.74%
Nikkei 225	45,303.43	513.1	1.15%	39,894.54	13.56%
FTSE 100	9,240.15	31.8	0.35%	8,132.56	13.62%

Market Statistics

Particulars	Today	Last Day	Daily Δ	Daily Δ %	60 Day MA
Turnover (BDT mn)	6,547	7,376	-829	-11.23%	8,459
Turnover (USD mn)	53	60	-7	-11.23%	71
Volume (mn)	211	218	-7	-3.10%	288
Market Cap (BDT bn)	7,245	7,260	-15	-0.21%	
Market Cap (USD bn)	59	59	0	-0.21%	
Market P/E (x)	11.9				
Particulars	Gain	Loser	Unchanged		
Market Breadth	44	303	50		

Sector Statistics

Sector	Market Cap (BDTmn)	% of total Market Cap	Sector Return	Turnover (BDTmn)	% of total turnover
Bank	710,963	19.65%	-0.5%	841.5	12.85%
Telecom	586,475	16.21%	-0.9%	171.0	2.61%
Pharma	582,714	16.10%	-0.7%	966.1	14.76%
Fuel & Power	312,075	8.62%	-0.1%	289.3	4.42%
Engineering	294,532	8.14%	-1.1%	602.0	9.19%
Food & Allied	268,383	7.42%	-0.6%	358.9	5.48%
Misc	235,148	6.50%	-0.3%	503.0	7.68%
Textile	128,660	3.56%	0.0%	845.7	12.92%
NBFI	104,074	2.88%	-2.0%	148.8	2.27%
Cement	97,753	2.70%	-1.7%	73.9	1.13%
G. Insurance	82,159	2.27%	-1.3%	143.6	2.19%
L. Insurance	55,279	1.53%	-1.7%	332.4	5.08%
Travel & Leisure	39,631	1.10%	-2.1%	112.5	1.72%
IT	27,209	0.75%	-0.2%	445.2	6.80%
Mutual Fund	26,616	0.74%	-1.4%	83.4	1.27%
Paper & Printing	24,239	0.67%	-3.3%	224.0	3.42%
Tannery	23,288	0.64%	-0.8%	51.2	0.78%
Services & Real Estate	20,922	0.58%	-1.4%	225.2	3.44%

Top Turnover

Ticker	Close Price (BDT)	Daily Δ %	Turnover (BDTmn)	Volume (mn)	P/E (x)
KBPPWBIL	163.30	1.05%	350.17	2.19	816.50
BRACBANK	70.50	-0.14%	209.79	2.97	9.90
SAPORTL	37.60	-1.83%	196.61	5.17	12.05
TECHNODRUG	40.70	5.17%	191.28	4.81	21.65
ISNLTD	108.30	-0.46%	176.93	1.59	n/a

Top Gainers

Ticker	Close Price (BDT)	Daily Δ %	Turnover (BDTmn)	Volume (mn)	P/E (x)
UCB	11.10	5.71%	125.00	11.37	46.25
TECHNODRUG	40.70	5.17%	191.28	4.81	21.65
ENVOYTEX	61.00	4.63%	151.62	2.49	7.59
APOLISPAT	2.80	3.70%	0.19	0.07	n/a
MATINSPINN	56.20	3.69%	50.04	0.89	11.52

Top Losers

Ticker	Close Price (BDT)	Daily Δ %	Turnover (BDTmn)	Volume (mn)	P/E (x)
CAPMBDBLMF	10.30	-8.85%	17.05	1.62	n/a
PRIMEFIN	2.10	-8.70%	2.75	1.25	n/a
PLFSL	1.10	-8.33%	0.50	0.43	n/a
FIRSTFIN	2.40	-7.69%	0.05	0.02	n/a
SIBL	4.10	-6.82%	4.55	1.10	n/a

Daily Market Review

Market closed negative

18-Sep-2025

RENATA

Renata PLC delivers Rivaroxaban Capsules to the Australian Market

The company has informed that it has successfully shipped its Rivaroxaban Capsules (15 mg and 20 mg) to Australia, marking the first availability of this important anticoagulant in capsule form in that market. The product has been manufactured at TGA-approved facility, underscoring Renata's commitment to meeting stringent global regulatory standards. This achievement not only broadens patient treatment options in Australia but also reflects Renata's steady progress in expanding its international footprint.

BSC

Board approval for acquisition of two new ships from China

The Board of Directors of the company in its meeting held on 17 - 09-2025 has approved the contract (to be signed between BSC and Hellenic Dry Bulk Ventures LLC) for acquisition of two new ships from China using BSC's own fund (about USD 76.698 million).

Block Trade

Ticker	Max Price (BDT)	Min Price (BDT)	No. of Trades	Volume	Value (BDTmn)
ACIFORMULA	154.8	154.8	2	15000	2.322
AL-HAJTEX	174	174	2	6000	1.044
AMANFED	26.4	26.4	1	94000	2.482
ASIATICLAB	62	60	3	508100	30.502
BRACBANK	74	68	4	2283000	161.024
CITYGENINS	60.5	60.5	1	9000	0.544
EHL	93	93	1	40000	3.72
EXIM1STMF	4.1	4.1	1	168300	0.69
FINEFOODS	290	285	3	67000	19.18
GOLDENSON	13.8	13.8	1	41000	0.566
GQBALLPEN	525	525	1	2150	1.129
HAKKANIPUL	80.5	80.5	1	12296	0.99
IFIC	5.8	5.8	1	100000	0.58
ISNLTD	119.6	119.6	1	58500	6.997
KBPPWBIL	149	145.5	9	338981	49.91
MEGHNACEM	53	53	1	25000	1.325
MJLBD	103	103	1	10000	1.03
MONNOAGML	416	416	1	1600	0.666
MONNOCERA	94	94	1	10000	0.94
NLTUTUBES	88.7	88.7	1	6900	0.612
ORIONINFU	500.1	500.1	1	1503	0.752
PRAGATILIF	187	187	1	3000	0.561
PTL	60.3	59.5	2	62920	3.77
RANFOUNDRY	186	186	1	9500	1.767
SINOBANGLA	60	58	2	24650	1.462
SIPLC	52.7	52.7	1	22000	1.159
STANDBANKL	5.3	5.3	1	102500	0.543
TECHNODRUG	39.5	39.5	1	12900	0.51
UCB	9.6	9.6	1	325000	3.12
UNIQUEHRL	47	47	1	12900	0.606

Disclaimer

For U.S. persons only: This research report is a product of UCB Stock Brokerage Ltd. ("UCB"), a company authorized to engage in securities activities in Bangladesh, under Marco Polo Securities 15a-6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

Research reports are intended for distribution by only to "Major Institutional Investors" as defined by Rule 15a-6 (b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a-6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, UCB has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be affected through Marco Polo or another U.S. registered broker dealer.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by UCB Stock Brokerage Limited (UCB) with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior consent of UCB and UCB accepts no liability whatsoever for the actions of third parties in this respect.

EQUITY RECOMMENDATION STRUCTURE (ABSOLUTE RATINGS)

We calculate our target price by weighting DCF, DDM, SOTP, asset-based and other relative valuation methods, and applying appropriate premiums/ discounts and/or other relevant adjustments.

Expected absolute returns are calculated as the % of difference between our target price and latest close price. Stock recommendations are based on absolute upside (downside) and have a 12-month horizon. Please note that future price fluctuations could lead to a temporary mismatch between upside/downside for a stock and our recommendation.

Recommendation Type	Holding period (if not otherwise mentioned)	Absolute Return Potential
Buy	12 Months	More than +15%
Neutral/ Hold	12 Months	Between -5% and +15%
Underweight	12 Months	Less than -5%

ANALYST CERTIFICATION

Respective analyst(s) identified in this report certifies, with respect to the companies or securities that the individual analyses, that (1) the views expressed in this report reflect his or her personal views about all of the subject companies and securities and (2) no part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this report. The research analyst(s) named on this report are not registered / qualified as research analysts with FINRA.

It has not been determined in advance whether and in what intervals this document will be updated. Unless otherwise stated current prices refer to the most recent trading day's closing price.

Contact Us

Research Team

Md. Hasib Reza, CFA	Head of Research	hasib.reza@ucbstock.com.bd	+880 1755 658 997
Anik Mahmood Ibne Anwar, CFA	Deputy Head of Research	anik.mahmood@ucbstock.com.bd	+880 1701 205 074
Fahmid Islam Sadhin	Research Associate	fahmid.islam@ucbstock.com.bd	+880 1325 086 738
Nafis Zaki	Research Associate	nafis.zaki@ucbstock.com.bd	+880 1871 891 263
Mahmudul Hasan Meraz	Research Associate	mahmudul.hasan@ucbstock.com.bd	+880 1324 719 456
Numair M N Ahmmed	Research Associate	ahmmed.numair@ucbstock.com.bd	+880 1324 719 484

Investment Strategist

Syed Adnan Huda, CFA	First Vice President	adnan@ucbstock.com.bd	+880 1730 325 232
----------------------	----------------------	-----------------------	-------------------

Institutional & Foreign Trade

Tahmidur Rahman	First Assistant Vice President	rahman.tahmidur@ucbstock.com.bd	+880 1726 995 520
-----------------	--------------------------------	---------------------------------	-------------------

Office Premises

Head Office

Gulshan

Bulus Center

+880 2955 8481

Extensions of Head Office

Dilkusha +880 1701 205 090	Dilkusha (NIK Tower) +880 1701 205 000	Dhanmondi +880 1713 205 703	Nikunja +880 1701 205 013	Mohammadpur +880 1324 243 212
Bashundhara +880 1718 106 217	Mirpur-1 +880 1713 205 723	Mirpur-12 +880 1911 197 188	Banasree +880 1701 205 075	Uttara +880 1913 128 156

Branch Offices

Chattogram +880 1701 205 038	Sylhet +880 1713 205 760
--	------------------------------------

Digital Booths

Khulna +880 1717 411 466	Barishal +880 1713 205 762	Cumilla +880 1324 243 163	Jashore +880 1324 243 203	Gazipur +880 1324 243 165
Feni +880 1324 243 210	Khatungonj +880 1713 205 742	Chawkbazar +880 1817 206 965	Madhobdi +880 1324 243 156	
	Narayangonj +880 1324 243 207	Agrabad +880 1324 243 198		